Literature DB >> 33630146

18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.

Fengxian Zhang1, Xiaodong Wu1, Junjie Zhu2, Yan Huang3, Xiao Song4, Lei Jiang5.   

Abstract

PURPOSE: This study retrospectively investigated the clinical utility of 2-deoxy-18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) and circulating tumor cells (CTCs) in the diagnosis and prognosis of treatment-naive patients with non-small-cell lung cancer (NSCLC).
METHODS: The blood samples of treatment-naive patients with NSCLC were collected for CTCs detection, and the tumor metabolic parameters of 18F-FDG PET/CT, including maximum standard uptake value (SUVmax), metabolic tumor volume of primary lesion (MTV-P) and combination of primary lesion and metastases (MTV-C), and total lesion glycolysis of primary lesion (TLG-P) and combination of primary lesion and metastases (TLG-C), were analyzed. Age, sex, smoking, serum tumor markers, tumor size, location, TNM stage, and genetic mutations were also reviewed. Moreover, progression-free survival (PFS) and overall survival (OS) of these patients were analyzed.
RESULTS: A total of 309 patients with NSCLC (200 men, 109 women; mean age: 61 ± 9 years) were enrolled in this study, including 217 patients with adenocarcinoma and 92 with squamous cell carcinoma. Of the 309 cases, 11 were misdiagnosed with benign diseases by 18F-FDG PET/CT. CTCs positivity was detected in 234 cases. The sensitivity of 18F-FDG PET/CT and CTCs in NSCLC were 96.4% and 75.7%, respectively. SUVmax, MTV-P, TLG-P, MTV-C, TLG-C, tumor size, and serum CYFRA211 levels were significantly higher in CTCs positive group than negative group; and advanced TNM stage, squamous cell carcinoma, and EGFR wild type presented higher CTCs positivity. Multivariate logistic regression analysis revealed that SUVmax was significantly associated with CTCs positivity. Multivariate cox regression analysis showed that TLG-P, TLG-C, and CTCs were independent predictors of PFS in patients with NSCLC, and TLG-C and CTCs were independent predictors of OS.
CONCLUSIONS: 18F-FDG PET/CT was superior to CTCs in the diagnosis of treatment-naive patients with NSCLC. The levels of CTCs in the peripheral blood were associated with tumor glucose metabolism in NSCLC. Metabolic parameters of 18F-FDG PET/CT and CTCs could separately predict the outcomes of treatment-naive patients with NSCLC.

Entities:  

Keywords:  18F-FDG PET/CT; Circulating tumor cells (CTCs); Diagnosis; Non-small-cell lung cancer (NSCLC); Prognosis

Year:  2021        PMID: 33630146     DOI: 10.1007/s00259-021-05260-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  31 in total

Review 1.  Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer.

Authors:  Asha Kandathil; Fernando U Kay; Yasmeen M Butt; Jason W Wachsmann; Rathan M Subramaniam
Journal:  Radiographics       Date:  2018 Nov-Dec       Impact factor: 5.333

2.  Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers.

Authors:  Clara I Bayarri-Lara; Diego de Miguel Pérez; Antonio Cueto Ladrón de Guevara; Antonio Rodriguez Fernández; Jose L Puche; Abel Sánchez-Palencia Ramos; Javier Ruiz Zafra; Carlos F Giraldo Ospina; Miguel Delgado-Rodríguez; Manuela Expósito Ruiz; Maria José Moyano Rodriguez; Jose A Lorente; Maria José Serrano
Journal:  Eur J Cardiothorac Surg       Date:  2017-07-01       Impact factor: 4.191

3.  Role of various semiquantitative parameters of 18F-FDG PET/CT studies for interim treatment response evaluation in non-small-cell lung cancer.

Authors:  Akshima Sharma; Anant Mohan; Ashu Seith Bhalla; Sreenivas Vishnubhatla; Anil Kumar Pandey; Chandra Sekhar Bal; Rakesh Kumar
Journal:  Nucl Med Commun       Date:  2017-10       Impact factor: 1.690

Review 4.  Lung Cancer Staging and Prognosis.

Authors:  Gavitt A Woodard; Kirk D Jones; David M Jablons
Journal:  Cancer Treat Res       Date:  2016

5.  Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.

Authors:  Elizabeth A Punnoose; Siminder Atwal; Weiqun Liu; Rajiv Raja; Bernard M Fine; Brett G M Hughes; Rodney J Hicks; Garret M Hampton; Lukas C Amler; Andrea Pirzkall; Mark R Lackner
Journal:  Clin Cancer Res       Date:  2012-04-05       Impact factor: 12.531

6.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

7.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

8.  Prognostic importance of 18F-fluorodeoxyglucose uptake by positron emission tomography for stage III non-small cell lung cancer treated with definitive chemoradiotherapy.

Authors:  G Kanyilmaz; B Benli Yavuz; M Aktan; O Sahin
Journal:  Rev Esp Med Nucl Imagen Mol (Engl Ed)       Date:  2019-10-24

Review 9.  Clinical usefulness of 18F-FDG PET/CT for the detection of distant metastases in patients with non-small cell lung cancer at initial staging: a meta-analysis.

Authors:  Binbin Yu; Xiaodong Zhu; Zhongguo Liang; Yongchu Sun; Wei Zhao; Kaihua Chen
Journal:  Cancer Manag Res       Date:  2018-07-04       Impact factor: 3.989

10.  Incorporation of circulating tumor cells and whole-body metabolic tumor volume of 18F-FDG PET/CT improves prediction of outcome in IIIB stage small-cell lung cancer.

Authors:  Lei Fu; Ying Zhu; Wang Jing; Dong Guo; Li Kong; Jinming Yu
Journal:  Chin J Cancer Res       Date:  2018-12       Impact factor: 5.087

View more
  5 in total

1.  Quantitative assessment of intratumoral 2-[18F]FDG metabolic spatial distribution in hypermetabolic pulmonary lesions in PET/CT.

Authors:  Ling Wang; Jia Jiang; Beihui Xue; Jie Lin; Xiaowei Ji; Xiangwu Zheng; Kun Tang
Journal:  Quant Imaging Med Surg       Date:  2022-07

2.  [68Ga-PSMA-I&T PET/CT for assessment of tumor burden in primary lesions of treatmentnaïve prostate cancer].

Authors:  Y Xie; C Li; L Zhang; S Zang; F Yu; S Wang; F Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-08-20

3.  Prognostic value of thoracic tumor staging and volume parameters in non-small cell lung cancer patients with synchronous solitary bone metastasis.

Authors:  Kan Deng; Shuping Li; Jian Zhang; Xiande Ye; Kai Yao; Ying Li; Jianru Xiao
Journal:  J Thorac Dis       Date:  2022-04       Impact factor: 3.005

4.  Distribution and Clinical Significance of IL-17A in Tumor-Infiltrating Lymphocytes of Non-Small Cell Lung Cancer Patients.

Authors:  Rui Xu; Xing Ke; Wenwen Shang; Shuna Liu; Xin Fu; Ting Wang; Shuxian Jin
Journal:  Pathol Oncol Res       Date:  2022-05-18       Impact factor: 2.874

5.  Metabolic activity via 18F-FDG PET/CT is predictive of microsatellite instability status in colorectal cancer.

Authors:  Jinling Song; Zhongwu Li; Lujing Yang; Maomao Wei; Zhi Yang; Xuejuan Wang
Journal:  BMC Cancer       Date:  2022-07-22       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.